February 02, 2026 a 07:43 pm
PFE: Fundamental Ratio Analysis - Pfizer Inc.
Pfizer Inc., a leading biopharmaceutical company, exhibits robust performance highlighted by its strong product pipeline and strategic collaborations. The current and historical fundamental ratings reflect its stability, although challenges in market dynamics persist. Investors should remain cautious about potential sector-specific risks.
Fundamental Rating
Pfizer Inc.'s fundamentals indicate a strong performance in discounted cash flow and return metrics, although debt to equity could be improved.
| Category | Score | Indicator |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return On Equity | 4 | |
| Return On Assets | 4 | |
| Debt To Equity | 1 | |
| Price To Earnings | 3 | |
| Price To Book | 4 |
Historical Rating
The historical data reflects that Pfizer Inc. has maintained consistent scoring over recent periods, indicating stability in its fundamental aspects.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-02-02 | 4 | 5 | 4 | 4 | 1 | 3 | 4 |
| - | 0 | 5 | 4 | 4 | 1 | 3 | 4 |
Analyst Estimates
Analysts predict a modest growth trajectory for Pfizer's stock, with varying price targets that emphasize stability.
| High | Low | Median | Consensus |
|---|---|---|---|
| $35 | $24 | $27.5 | $28 |
Analyst Sentiment
Analyst consensus for Pfizer Inc. remains in the 'Hold' category, with a significant portion recommending holding the stock.
| Rating | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 13 | |
| Hold | 23 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Pfizer Inc. is positioned as a strong player in the biopharmaceutical sector, supported by a reliable portfolio and strategic alliances. While the fundamental analysis underscores its strengths, particularly in cash flow and returns, attention should be given to its debt position. Analysts' 'Hold' consensus suggests moderate expectations, indicating a stock poised for stability rather than aggressive growth. Investors should weigh sector risks alongside Pfizer's innovative potential.